794-P: Effect of Liraglutide on Abdominal Fat Distribution and Glucose Metabolism in Chinese Patients with Obesity

Introduction 0.001). TC and LDL-c were sharply reduced (P=0.004, P=0.027 respectively). LFC was strikingly more in subjects with impaired glucose regulation (IGR) group compared to those with normal glucose tolerance (NGT) at baseline (P=0.002). The decreased LFC in IGR group was significantly greater after liraglutide treatment than those with NGT (P0.001). Linear regression analysis showed that HOMA-IR at baseline was the independent marker for LFC reduction after liraglutide treatment (B: 0.634; 95%CI:0.100-1.168, P=0.021). Conclusion: Liraglutide monotherapy for 12 weeks significantly reduced LFC in patients with obesity. The LFC reduction may serve as one of possible mechanisms of blood glucose improvement in obese patients. Disclosure M. Du: None. J. Yue: None. Y. Qi: None. S. He: None. X. Lu: None. M. Yang: None. L. Wang: None. Q. Lu: None. J. Ma: None.